Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Multiple Myeloma
Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.
Plasma Cell Dyscrasias
This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström’s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.
Bortezomib in the Treatment of Multiple Myeloma
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Cancer Precursor Conditions and their Detection, An Issue of Hematology/Oncology Clinics of North America
In this issue of Hematology/Oncology Clinics, guest editor Dr. Elizabeth K. O'Donnell brings her considerable expertise to the topic of Cancer Precursor Syndromes and Their Detection. Top experts focus on cancer precursors for different sites, with articles on the risk-benefit analysis of early interception; plasma cell precursors; early detection and interception of lung cancer, cervical cancer, GI cancers, skin cancer; and head and neck cancer; biomarkers and early detection; and more. - Contains 12 relevant, practice-oriented topics including clonal hematopoiesis of indeterminate potential (CHIP); prostate cancer: early detection and intervention; ductal carcinoma in situ; cancer prevention; and more. - Provides in-depth clinical reviews on cancer precursor syndromes and their detection, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Advances in Biology and Therapy of Multiple Myeloma
Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecula...
Consultative Hematology, An Issue of Hematology/Oncology Clinics of North America
Topics include: Why does my patient have leukocytosis?, Why Is My Patient Neutropenic?, Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?, DVT and Pulmonary Embolism, Why Does My Patient Have Lymphadenopathy/Splenomegaly?,and Why Does My Patient have Thrombocytopenia?
Non-Hodgkin Lymphoma
This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided on current standard treatment options, including stem cell transplantation as well as new cutting-edge therapeutics.
Recent Advances in Angiogenesis and Antiangiogenesis
"The book presents recent advances in the field of angiogenesis and antiangiogenesis. Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research now has a solid scientific foundation. Tumor growth, meta"
Immunomodulating Drugs for the Treatment of Cancer
Immunomodulating Drugs for the Treatment of Cancer provides a comprehensive resource for clinicians and researchers regarding immunomodulatory (IMiDs) drugs and their rapidly emerging role in cancer medicine. This new class of anticancer agents has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity.
